Analgesic drug to treat neuropathic pain induced by chemotherapies

Oxaliplatin-based cancer treatments induce neuropathic pain which can lead to decrease or stop treatment, with the risk of limiting the effective clinical outcome. Current treatments for this pain display side-effects and weak efficiency.

Described here is a new asset that consists in :

1 | Repurposing of Donepezil, a centrally active acetylcholinesterase

inhibitor initially prescribed in Alzheimer’s disease as a solution to cure neuropathic pain induced by neurotoxic chemotherapies.

2 | Reduction of associated comorbidities

Competitive Advantages

● Response to unmet therapeutic need

● Attractive to speed up drug development

● Contribute to life quality improvement

● Preventive and curative analgesic effects

● Non-opioid

Development Status

● In vivo POC in oxaliplatin induced neuropathic rat models

● Validation of the MoA based on key role of muscarinic M2 receptors

in Donepezil-induced antinociception

Business Opportunities

● Chronic pain Treatment : in combination of cancer chemotherapy to prevent/suppress drug-evoked neuropathies